Stock Analysis, Dividends, Split History

ALBO / Albireo Pharma, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)306.31
Enterprise Value ($M)123.08
Book Value ($M)149.45
Book Value / Share12.49
Price / Book2.05
NCAV ($M)131.56
NCAV / Share10.99
Price / NCAV2.37
Share Statistics
Common Shares Outstanding 11,897,146
Common Stock Shares Outstanding 8,902,784
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.37
Return on Assets (ROA)-0.85
Return on Equity (ROE)-0.92
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio23.53
Income Statement (mra) ($M)
Sales Revenue Goods Net1,000.00
Revenue From Grants0.00
Operating Income-24.58
Net Income-24.41
Earnings Per Share Diluted-3.12
Earnings Per Share Basic-3.12
Earnings Per Share Basic And Diluted-3.12
Cash Flow Statement (mra) ($M)
Cash From Operations-27.57
Cash from Investing4.31
Cash from Financing-27.57
Identifiers and Descriptors
Central Index Key (CIK)1322505

Split History

Stock splits are used by Albireo Pharma, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

Gilead In PBC: The Clinical Pursuit For Dominance

8h seekingalpha
The continual decline in sale revenues generated from therapeutics for viral liver diseases could be a contributing factor. (8-0)

Genfit And PBC: Is Elafibranor A Contender?

2018-10-10 seekingalpha
Elafibranor, a metabolism modulator, is a dual PPAR-α/b agonist that is being evaluated clinically for therapeutic efficacy in Phase 3 NASH along with Phase 2 PBC. (0-1)

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2018 Results - Earnings Call Transcript

2018-08-07 seekingalpha
Good morning, ladies and gentlemen, and thank you for joining us for Albireo's Conference Call to provide a Business Update for the First-Half of 2018. Following some prepared remarks from the company, we'll open the call for questions.

Albireo And A4250: The Pediatric Remedy Making Waves

2018-07-30 seekingalpha
A4250 is a Phase 3 anti-cholestasis pediatric orphan disease drug candidate in clinical trial for the rare progressive pediatric genetic liver disease Progressive Familial Intrahepatic Cholestasis. (14-0)

CUSIP: 09064M204